Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents

被引：15
|
作者：
Liu, Shangde [1 ]
Li, Shanshan [1 ]
Yuan, Duo [1 ]
Wang, Enmao [1 ]
Xie, Roujie [1 ]
Zhang, Weiqi [1 ]
Kong, Yi [2 ]
Zhu, Xiong [1 ]
机构：
[1] China Pharmaceut Univ, Inst Med & Chem, Nanjing 210009, Peoples R China
[2] China Pharmaceut Univ, Sch Life & Technol, Nanjing 210009, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2021年 / 209卷
关键词：
PAR4; Small-molecule antagonists; Antiplatelet agents; SAR; Structural optimization; BMS-986120; BMS-986141; Preclinical trials; Clinical trials; ACUTE CORONARY SYNDROMES; THROMBIN-RECEPTOR; PLATELET ACTIVATION; THROMBOXANE PRODUCTION; IN-VITRO; INHIBITION; YD-3; AGGREGATION; DISCOVERY; PEPTIDES;
D O I：
10.1016/j.ejmech.2020.112893
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Protease activated receptor 4 (PAR4) is a key target in antiplatelet medication to reduce the risk of heart attack and thrombotic complications in stroke. PAR4 antagonists can prevent harmful and stable thrombus growth while retaining initial thrombus formation by acting on the late diffusion stage of platelet activation, which may provide a safer alternative than other antiplatelet agents. Currently, research on PAR4 antagonists is of increasing interest in the field of antiplatelet agents. This article provides an overview of the discovery and development of small-molecule antagonists of PAR4 as novel antiplatelet agents, including structure-activity relationship (SAR) analysis, progress of structure and bioassay optimization, and the latest structural and/or clinical information of representative small-molecule antagonists of PAR4. (c) 2020 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数：15
相关论文
共 50 条
  • [1] Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy
    Rudinga, Gamariel Rwibasira
    Khan, Ghulam Jilany
    Kong, Yi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (02)
  • [2] PAR4 (Protease-Activated Receptor 4) PARticularly Important 4 Antiplatelet Therapy
    Han, Xu
    Nieman, Marvin T.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38 (02) : 287 - 289
  • [3] Mapping the Protease Activated Receptor 4 (PAR4) Homodimer Interface
    Nieman, Marvin T.
    BLOOD, 2009, 114 (22) : 320 - 320
  • [4] Discovery of Protease-Activated Receptor 4 (PAR4)-Tethered Ligand Antagonists Using Ultralarge Virtual Screening
    Smith, Shannon T.
    Cassada, Jackson B.
    Von Bredow, Lukas
    Erreger, Kevin
    Webb, Emma M.
    Trombley, Trevor A.
    Kalbfleisch, Jacob J.
    Bender, Brian J.
    Zagol-Ikapitte, Irene
    Kramlinger, Valerie M.
    Bouchard, Jacob L.
    Mitchell, Sidnee G.
    Tretbar, Maik
    Shoichet, Brian K.
    Lindsley, Craig W.
    Meiler, Jens
    Hamm, Heidi E.
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2024, 7 (04) : 1086 - 1100
  • [5] Evidence for the presence of functional protease activated receptor 4 (PAR4) in the rat colon
    Mulè, F
    Pizzuti, R
    Capparelli, A
    Vergnolle, N
    GUT, 2004, 53 (02) : 229 - 234
  • [6] Development and characterization of monoclonal antibodies against Protease Activated Receptor 4 (PAR4)
    Mumaw, Michele M.
    de la Fuente, Maria
    Arachiche, Amal
    Wahl, James K., III
    Nieman, Marvin T.
    THROMBOSIS RESEARCH, 2015, 135 (06) : 1165 - 1171
  • [7] Analysis of Protease Activated Receptor 4 (PAR4) By Histidine Hydrogen Deuterium Exchange
    Nieman, Marvin T.
    de la Fuente, Maria
    Miyagi, Masaru
    BLOOD, 2014, 124 (21)
  • [8] Protease-activated receptor PAR4 drives cardiac inflammatin in diabetes
    Fender, A.
    Stolte, S.
    Leineweber, K.
    Kamler, M.
    Dobrev, D.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2020, 393 (SUPPL 1) : 13 - 13
  • [9] Mapping the interaction of peptide RPPGF with the exodomain on human protease activated receptor 4 (PAR4).
    Nieman, MT
    Pagan-Ramos, E
    Warnock, M
    Krijanovski, Y
    Hasan, AAK
    Schmaier, AH
    BLOOD, 2004, 104 (11) : 511A - 512A
  • [10] Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis
    Zhang, Xiaojun
    Jiang, Wen
    Richter, Jeremy M.
    Bates, J. Alex
    Reznik, Samuel K.
    Stachura, Sylwia
    Rampulla, Richard
    Doddalingappa, Dyamanna
    Ulaganathan, Sankar
    Hua, Ji
    Bostwick, Jeffrey S.
    Sum, Chi
    Posy, Shana
    Malmstrom, Sarah
    Dickey, Joyce
    Harden, David
    Lawrence, R. Michael
    Guarino, Victor R.
    Schumacher, William A.
    Wong, Pancras
    Yang, Jing
    Gordon, David A.
    Wexler, Ruth R.
    Priestley, Scott
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (05) : 3571 - 3589
12345